Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China's Simcere Signs Novel Licensing Agreement Covering U.S.-based OSI Pharmaceutical's Cancer Drug

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Simcere Pharmaceutical, a leading Chinese drug and biotech firm, has signed an agreement with the U.S.-based OSI Pharmaceutical to license OSI's cancer treatment candidate OSI-930 in China

You may also be interested in...



Merck, Simcere Form JV To Expand Access To Lifestyle Drugs Across China

SHANGHAI - Merck & Co. affiliate MSD signed an agreement to form a joint venture July 21 with Simcere Pharmaceutical Group that will see both companies expand access to critical lifestyle drugs across China

Merck, Simcere Form JV To Expand Access To Lifestyle Drugs Across China

SHANGHAI - Merck & Co. affiliate MSD signed an agreement to form a joint venture July 21 with Simcere Pharmaceutical Group that will see both companies expand access to critical lifestyle drugs across China

China's Simcere Reports Slow Q1 Results, But Sales Force Reorganization Could Help Attract New Pharma Partners

SHANGHAI - Simcere Pharmaceutical Group, one of the first Chinese domestic pharmaceutical companies to list in the U.S., reported a slow first quarter result due to slower than expected sales of lead product line first-to-market edavarone injection branded Bicun and Yidasheng.

Related Content

UsernamePublicRestriction

Register

LL1133273

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel